Biohaven Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BHVN New York 2834 www.biohaven.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biohaven Ltd.

Pfizer Inc. Q3 2026 Earnings Call Summary - Nov 3rd, 2026 3:44 pm
Is Biohaven (BHVN) Undervalued After Its Narrower Loss And BHV 1420 Data? - Oct 30th, 2026 9:10 am
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results - Oct 29th, 2026 2:02 pm
Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade - Oct 29th, 2026 6:55 am
JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight - Oct 26th, 2026 8:31 am
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy - Oct 26th, 2026 5:30 am
Biohaven Could Transform With Troriluzole's FDA Approval, RBC Says - Oct 23rd, 2026 9:56 am
Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review Acceptance - Oct 23rd, 2026 5:18 am
Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade - Oct 22nd, 2026 8:28 pm
Why Biohaven Catapulted 25% — And Why It Might Not Be Done Sprinting - Oct 22nd, 2026 2:23 pm
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again - Oct 22nd, 2026 11:29 am
Biohaven’s previously rejected rare disease drug to get fresh FDA review - Oct 22nd, 2026 10:24 am
BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia - Oct 22nd, 2026 7:27 am
Biohaven stock surges 25% on FDA acceptance of drug filing - Oct 22nd, 2026 5:43 am
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights - Oct 9th, 2026 7:12 pm
Biohaven partners with Ono in $100m IgG degrader deal - Oct 9th, 2026 3:00 am
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease - Oct 8th, 2026 2:00 am
Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron? - Oct 8th, 2026 12:18 am
Roche’s AI lab; Biohaven’s pivotal pause - Oct 2nd, 2026 7:54 am